Another study found that plasma exosomal PD-L1 levels were significantly reduced in patients with complete or partial remission, but increased in patients with progressive melanoma or NSCLC after two months of treatment with either the anti-PD-1 antibody nivolumab or pembrolizumab [60]. The gene discussed is PDCD1; the disease is melanoma.